185 related articles for article (PubMed ID: 37486991)
1. EYA2 tyrosine phosphatase inhibition reduces MYC and prevents medulloblastoma progression.
Wolin AR; Vincent MY; Hotz T; Purdy SC; Rosenbaum SR; Hughes CJ; Hsu JY; Oliphant MUJ; Armstrong B; Wessells V; Varella-Garcia M; Galbraith MD; Pierce A; Wang D; Venkataraman S; Danis E; Veo B; Serkova N; Espinosa JM; Gustafson DL; Vibhakar R; Ford HL
Neuro Oncol; 2023 Dec; 25(12):2287-2301. PubMed ID: 37486991
[TBL] [Abstract][Full Text] [Related]
2. Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma.
Chaturvedi NK; Mahapatra S; Kesherwani V; Kling MJ; Shukla M; Ray S; Kanchan R; Perumal N; McGuire TR; Sharp JG; Joshi SS; Coulter DW
BMC Cancer; 2019 Nov; 19(1):1056. PubMed ID: 31694585
[TBL] [Abstract][Full Text] [Related]
3. A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma.
Kling MJ; Kesherwani V; Mishra NK; Alexander G; McIntyre EM; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
J Exp Clin Cancer Res; 2022 Nov; 41(1):321. PubMed ID: 36357906
[TBL] [Abstract][Full Text] [Related]
4. MYC up-regulation confers vulnerability to dual inhibition of CDK12 and CDK13 in high-risk Group 3 medulloblastoma.
Pitolli C; Marini A; Guerra M; Pieraccioli M; Marabitti V; Palluzzi F; Giacò L; Tamburrini G; Cecconi F; Nazio F; Sette C; Pagliarini V
J Exp Clin Cancer Res; 2023 Aug; 42(1):214. PubMed ID: 37599362
[TBL] [Abstract][Full Text] [Related]
5. Marinopyrrole derivative MP1 as a novel anti-cancer agent in group 3 MYC-amplified Medulloblastoma.
Coulter DW; Chhonker YS; Kumar D; Kesherwani V; Aldhafiri WN; McIntyre EM; Alexander G; Ray S; Joshi SS; Li R; Murry DJ; Chaturvedi NK
J Exp Clin Cancer Res; 2024 Jan; 43(1):18. PubMed ID: 38200580
[TBL] [Abstract][Full Text] [Related]
6. Bone morphogenetic protein-7 is a MYC target with prosurvival functions in childhood medulloblastoma.
Fiaschetti G; Castelletti D; Zoller S; Schramm A; Schroeder C; Nagaishi M; Stearns D; Mittelbronn M; Eggert A; Westermann F; Ohgaki H; Shalaby T; Pruschy M; Arcaro A; Grotzer MA
Oncogene; 2011 Jun; 30(25):2823-35. PubMed ID: 21317922
[TBL] [Abstract][Full Text] [Related]
7. Anti-proliferative activity of the quassinoid NBT-272 in childhood medulloblastoma cells.
von Bueren AO; Shalaby T; Rajtarova J; Stearns D; Eberhart CG; Helson L; Arcaro A; Grotzer MA
BMC Cancer; 2007 Jan; 7():19. PubMed ID: 17254356
[TBL] [Abstract][Full Text] [Related]
8. Dissecting super-enhancer driven transcriptional dependencies reveals novel therapeutic strategies and targets for group 3 subtype medulloblastoma.
Li M; Han Y; Wang C; Kang W; Jiang W; Zhang L; Tang Y
J Exp Clin Cancer Res; 2022 Oct; 41(1):311. PubMed ID: 36273157
[TBL] [Abstract][Full Text] [Related]
9. PUMC-MB1 is a novel group 3 medulloblastoma preclinical model, sensitive to PI3K/mTOR dual inhibitor.
Wang S; Zhang D; Wang J; Peng X; Sun H; Ji Y; Yang Z; Bian X; Hou Y; Ge M; Liu Y
J Neurooncol; 2024 May; 168(1):139-149. PubMed ID: 38662151
[TBL] [Abstract][Full Text] [Related]
10. Targeting B7‑H3 through EZH2 inhibition in MYC‑positive Group 3 medulloblastoma.
Shishido K; Purvis IJ; Velpula KK; Venkataraman S; Vibhakar R; Asuthkar S
Oncol Rep; 2023 Jun; 49(6):. PubMed ID: 37114557
[TBL] [Abstract][Full Text] [Related]
11. Cancer-selective metabolic vulnerabilities in MYC-amplified medulloblastoma.
Gwynne WD; Suk Y; Custers S; Mikolajewicz N; Chan JK; Zador Z; Chafe SC; Zhai K; Escudero L; Zhang C; Zaslaver O; Chokshi C; Shaikh MV; Bakhshinyan D; Burns I; Chaudhry I; Nachmani O; Mobilio D; Maich WT; Mero P; Brown KR; Quaile AT; Venugopal C; Moffat J; Montenegro-Burke JR; Singh SK
Cancer Cell; 2022 Dec; 40(12):1488-1502.e7. PubMed ID: 36368321
[TBL] [Abstract][Full Text] [Related]
12. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.
Henssen A; Thor T; Odersky A; Heukamp L; El-Hindy N; Beckers A; Speleman F; Althoff K; Schäfers S; Schramm A; Sure U; Fleischhack G; Eggert A; Schulte JH
Oncotarget; 2013 Nov; 4(11):2080-95. PubMed ID: 24231268
[TBL] [Abstract][Full Text] [Related]
13. Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells.
Vollmer J; Ecker J; Hielscher T; Valinciute G; Ridinger J; Jamaladdin N; Peterziel H; van Tilburg CM; Oehme I; Witt O; Milde T
J Neurooncol; 2023 Sep; 164(3):617-632. PubMed ID: 37783879
[TBL] [Abstract][Full Text] [Related]
14. RNA interference screening identifies a novel role for PCTK1/CDK16 in medulloblastoma with c-Myc amplification.
Ćwiek P; Leni Z; Salm F; Dimitrova V; Styp-Rekowska B; Chiriano G; Carroll M; Höland K; Djonov V; Scapozza L; Guiry P; Arcaro A
Oncotarget; 2015 Jan; 6(1):116-29. PubMed ID: 25402633
[TBL] [Abstract][Full Text] [Related]
15. Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma.
Han Y; Lindner S; Bei Y; Garcia HD; Timme N; Althoff K; Odersky A; Schramm A; Lissat A; Künkele A; Deubzer HE; Eggert A; Schulte JH; Henssen AG
Cancer Lett; 2019 Mar; 445():24-33. PubMed ID: 30611741
[TBL] [Abstract][Full Text] [Related]
16. Structural and Functional Analyses of an Allosteric EYA2 Phosphatase Inhibitor That Has On-Target Effects in Human Lung Cancer Cells.
Anantharajan J; Zhou H; Zhang L; Hotz T; Vincent MY; Blevins MA; Jansson AE; Kuan JWL; Ng EY; Yeo YK; Baburajendran N; Lin G; Hung AW; Joy J; Patnaik S; Marugan J; Rudra P; Ghosh D; Hill J; Keller TH; Zhao R; Ford HL; Kang C
Mol Cancer Ther; 2019 Sep; 18(9):1484-1496. PubMed ID: 31285279
[TBL] [Abstract][Full Text] [Related]
17. Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma.
Bolin S; Borgenvik A; Persson CU; Sundström A; Qi J; Bradner JE; Weiss WA; Cho YJ; Weishaupt H; Swartling FJ
Oncogene; 2018 May; 37(21):2850-2862. PubMed ID: 29511348
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma.
Diaz RJ; Golbourn B; Faria C; Picard D; Shih D; Raynaud D; Leadly M; MacKenzie D; Bryant M; Bebenek M; Smith CA; Taylor MD; Huang A; Rutka JT
Oncotarget; 2015 Feb; 6(5):3359-74. PubMed ID: 25739120
[TBL] [Abstract][Full Text] [Related]
19. Modeling medulloblastoma in vivo and with human cerebellar organoids.
Ballabio C; Anderle M; Gianesello M; Lago C; Miele E; Cardano M; Aiello G; Piazza S; Caron D; Gianno F; Ciolfi A; Pedace L; Mastronuzzi A; Tartaglia M; Locatelli F; Ferretti E; Giangaspero F; Tiberi L
Nat Commun; 2020 Jan; 11(1):583. PubMed ID: 31996670
[TBL] [Abstract][Full Text] [Related]
20. Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137.
Wang J; Sui Y; Li Q; Zhao Y; Dong X; Yang J; Liang Z; Han Y; Tang Y; Ma J
Cell Death Dis; 2020 Dec; 11(12):1029. PubMed ID: 33268769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
